argenx (ARGX) Competitors $644.48 -3.01 (-0.46%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$645.09 +0.61 (+0.09%) As of 02/21/2025 04:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ARGX vs. SNY, GSK, TAK, BNTX, ONC, TEVA, SMMT, GMAB, ITCI, and VTRSShould you be buying argenx stock or one of its competitors? The main competitors of argenx include Sanofi (SNY), GSK (GSK), Takeda Pharmaceutical (TAK), BioNTech (BNTX), Beigene (ONC), Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Genmab A/S (GMAB), Intra-Cellular Therapies (ITCI), and Viatris (VTRS). These companies are all part of the "pharmaceutical products" industry. argenx vs. Sanofi GSK Takeda Pharmaceutical BioNTech Beigene Teva Pharmaceutical Industries Summit Therapeutics Genmab A/S Intra-Cellular Therapies Viatris Sanofi (NASDAQ:SNY) and argenx (NASDAQ:ARGX) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, community ranking, dividends, media sentiment, institutional ownership and valuation. Which has more volatility & risk, SNY or ARGX? Sanofi has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, argenx has a beta of 0.58, suggesting that its share price is 42% less volatile than the S&P 500. Do analysts prefer SNY or ARGX? Sanofi currently has a consensus price target of $60.00, suggesting a potential upside of 10.17%. argenx has a consensus price target of $658.39, suggesting a potential upside of 2.16%. Given Sanofi's stronger consensus rating and higher probable upside, research analysts plainly believe Sanofi is more favorable than argenx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sanofi 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 2 Strong Buy rating(s) 3.25argenx 1 Sell rating(s) 2 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.86 Do insiders & institutionals have more ownership in SNY or ARGX? 14.0% of Sanofi shares are held by institutional investors. Comparatively, 60.3% of argenx shares are held by institutional investors. 1.0% of Sanofi shares are held by company insiders. Comparatively, 2.4% of argenx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Does the media favor SNY or ARGX? In the previous week, Sanofi had 13 more articles in the media than argenx. MarketBeat recorded 23 mentions for Sanofi and 10 mentions for argenx. argenx's average media sentiment score of 1.04 beat Sanofi's score of 1.02 indicating that argenx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sanofi 12 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive argenx 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SNY or ARGX more profitable? Sanofi has a net margin of 12.77% compared to argenx's net margin of -2.11%. Sanofi's return on equity of 25.61% beat argenx's return on equity.Company Net Margins Return on Equity Return on Assets Sanofi12.77% 25.61% 14.72% argenx -2.11%-1.45%-1.29% Which has higher valuation & earnings, SNY or ARGX? Sanofi has higher revenue and earnings than argenx. argenx is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSanofi$44.46B3.11$6.02B$2.4921.87argenx$1.27B30.87-$295.05M-$0.88-732.36 Does the MarketBeat Community prefer SNY or ARGX? argenx received 597 more outperform votes than Sanofi when rated by MarketBeat users. Likewise, 67.19% of users gave argenx an outperform vote while only 60.98% of users gave Sanofi an outperform vote. CompanyUnderperformOutperformSanofiOutperform Votes5060.98% Underperform Votes3239.02% argenxOutperform Votes64767.19% Underperform Votes31632.81% SummarySanofi beats argenx on 11 of the 19 factors compared between the two stocks. Get argenx News Delivered to You Automatically Sign up to receive the latest news and ratings for ARGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARGX vs. The Competition Export to ExcelMetricargenxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$39.16B$3.12B$5.84B$9.14BDividend YieldN/A1.56%4.76%3.85%P/E Ratio-732.3613.1718.2614.95Price / Sales30.87269.91434.4770.76Price / CashN/A177.4438.4235.17Price / Book9.313.687.644.65Net Income-$295.05M-$71.72M$3.18B$245.69M7 Day Performance0.79%-2.46%-1.95%-2.68%1 Month Performance0.73%-0.25%-0.23%-2.16%1 Year Performance58.74%-12.31%16.69%12.90% argenx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARGXargenx2.5004 of 5 stars$644.48-0.5%$658.39+2.2%+61.1%$39.34B$1.27B-732.361,148News CoveragePositive NewsSNYSanofi4.1036 of 5 stars$54.50+0.9%$60.00+10.1%+13.6%$138.31B$44.46B21.8986,088Analyst RevisionGSKGSK3.2601 of 5 stars$36.20-1.0%$43.25+19.5%-12.7%$75.02B$40.10B22.7670,200Gap DownTAKTakeda Pharmaceutical2.335 of 5 stars$13.54-0.6%N/A-4.4%$43.07B$28.20B33.8449,281Positive NewsBNTXBioNTech2.4325 of 5 stars$119.83-2.4%$142.72+19.1%+29.4%$28.73B$4.13B-57.066,133Positive NewsONCBeigeneN/A$230.86+2.4%N/AN/A$22.56B$2.46B-28.0210,600Insider TradeNews CoverageGap UpTEVATeva Pharmaceutical Industries2.8895 of 5 stars$16.24-2.4%$23.57+45.2%+28.8%$18.39B$16.54B-11.2037,851SMMTSummit Therapeutics2.3117 of 5 stars$21.37-2.1%$33.57+57.1%+438.2%$15.76B$700,000.00-76.32110Gap UpGMABGenmab A/S4.5905 of 5 stars$21.30+1.8%$42.17+98.0%-22.8%$14.10B$2.39B20.682,204ITCIIntra-Cellular Therapies3.8866 of 5 stars$127.82-0.2%$103.62-18.9%+75.5%$13.59B$464.37M-146.92560Earnings ReportAnalyst ForecastNews CoverageVTRSViatris2.0155 of 5 stars$10.80flat$13.67+26.5%-15.2%$12.89B$15.43B-14.5938,000News Coverage Related Companies and Tools Related Companies SNY Alternatives GSK Alternatives TAK Alternatives BNTX Alternatives ONC Alternatives TEVA Alternatives SMMT Alternatives GMAB Alternatives ITCI Alternatives VTRS Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARGX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersEx-CIA Advisor: Trump 2.0 Could “Send Gold to $10,000”Experts forecast gold's price racing to $4,000… and an ex-CIA advisor predicts we'll see gold hit $10,000. ...Colonial Metals | SponsoredAlert: DOGE goes live"It's Elon's world, and the rest of us live in it." Every investor in America is trying to figure out what ...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | SponsoredA strange twist 500 miles from WashingtonEnergy is life. And this year, it could also make national heroes out of President Trump and VP Vance. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding argenx SE Please log in to your account or sign up in order to add this asset to your watchlist. Share argenx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
